Investigational Drug Information for Verinurad
✉ Email this page to a colleague
What is the drug development status for Verinurad?
Verinurad is an investigational drug.
There have been 9 clinical trials for Verinurad.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 23rd 2019.
The most common disease conditions in clinical trials are Renal Insufficiency, Chronic, Kidney Diseases, and Hyperuricemia. The leading clinical trial sponsors are AstraZeneca, Parexel, and Contract Research Organization: USA.
There are twelve US patents protecting this investigational drug and one hundred and eighty international patents.
Summary for Verinurad
| US Patents | 12 |
| International Patents | 180 |
| US Patent Applications | 35 |
| WIPO Patent Applications | 17 |
| Japanese Patent Applications | 9 |
| Clinical Trial Progress | Phase 2 (2019-07-23) |
| Vendors | 44 |
Recent Clinical Trials for Verinurad
| Title | Sponsor | Phase |
|---|---|---|
| A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol | Parexel | Phase 1 |
| A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol | AstraZeneca | Phase 1 |
| Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers | Parexel | Phase 1 |
Clinical Trial Summary for Verinurad
Top disease conditions for Verinurad
Top clinical trial sponsors for Verinurad
US Patents for Verinurad
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Verinurad | ⤷ Sign Up | 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same | ARDEA BIOSCIENCES, INC. (San Diego, CA) | ⤷ Sign Up |
| Verinurad | ⤷ Sign Up | Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (Shanghai, CN) | ⤷ Sign Up |
| Verinurad | ⤷ Sign Up | Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (Shanghai, CN) | ⤷ Sign Up |
| Verinurad | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Verinurad | ⤷ Sign Up | URAT1 inhibitor | Nippon Chemiphar Co., Ltd. (Tokyo, JP) J-Pharma Co., Ltd. (Kanagawa, JP) DeThree Res. Lab. Inc. (Ibaraki, JP) | ⤷ Sign Up |
| Verinurad | ⤷ Sign Up | Thioacetate compounds, compositions and methods of use | Ardea Biosciences, Inc. (San Diego, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Verinurad
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Verinurad | Australia | AU2012332154 | 2031-11-03 | ⤷ Sign Up |
| Verinurad | Brazil | BR112014010495 | 2031-11-03 | ⤷ Sign Up |
| Verinurad | Canada | CA2852490 | 2031-11-03 | ⤷ Sign Up |
| Verinurad | China | CN104023723 | 2031-11-03 | ⤷ Sign Up |
| Verinurad | China | CN106963761 | 2031-11-03 | ⤷ Sign Up |
| Verinurad | Denmark | DK2776028 | 2031-11-03 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
